## CYTOKINE AND CAM ANTAGONISTS PRIOR AUTHORIZATION REQUEST

PRESCRIBER FAX FORM

ONLY the prescriber may complete and fax this form. This form is for prospective, concurrent, and retrospective reviews.

Incomplete forms will be returned for additional information. The following documentation is required for prior authorization consideration. For formulary information and to download additional forms, please visit https://www.bcbstx.com/provider/medicaid/rx\_prior\_auth.html PATIENT AND INSURANCE INFORMATION Today's Date: Patient Name (First): Last: DOB (mm/dd/yy): Patient Address: City, State, Zip: Patient Telephone: BCBSTX ID Number: Group Number: PRESCRIBER/CLINIC INFORMATION Prescriber Name: Prescriber NPI#: Specialty: Contact Name: Clinic Name: Clinic Address: City, State, Zip: Phone #: Secure Fax #: PLEASE ATTACH ANY ADDITIONAL INFORMATION THAT SHOULD BE CONSIDERED WITH THIS REQUEST

Patient's Diagnosis- ICD code plus description.							
Medication Requested:		Strength:					
Dosing Schedule:		Quantity per Month:					
1.	Is the patient currently treated with the requested medication?		Yes 🗌 No				
	If yes, when was treatment with the requested medication started?						
2.	. Has the patient had any of the following conditions in the last 730 days? (check all that apply)						
	☐ Ankylosing spondylitis	☐ Crohn's disease					
	Cryopyrin-associated periodic syndrome (CAPS)	Familial cold auto-inflammatory syndro	ome (FCAS)				
	☐ Familial Mediterranean fever (FMF)	☐ Giant cell arteritis (GCA)	, ,				
	☐ Hidradenitis suppurativa (HS)	☐ Hyperimmunoglobulin D syndrome (HI	DS)				
	☐ Mevalonate kinase deficiency (MKD)	☐ Moderate-to-severe plaque psoriasis					
	☐ Muckle-Wells syndrome (MWS)	☐ Polyarticular juvenile idiopathic arthritis	s (PJIA)				
	☐ Psoriatic arthritis (PA)	☐ Rheumatoid arthritis (RA)					
	Systemic juvenile idiopathic arthritis (SJIA)	☐ Ulcerative colitis (UC)					
	☐ Tumor necrosis factor receptor-associated periodic syndrome (TRAPS	, , ,					
	Cytokine release syndrome (CRS)	☐ Non-radiographic axial spondyloarthriti					
	Oral ulcers associated with Behcet's disease	☐ Other:					
3.	B. Does the patient have a history of a demyelinating disease (multiple sclerosis, optic neuritis, Guillain-Barre						
	syndrome) in the last 365 days?						
	Does the patient have a history of heart failure in the last 365 days?						
5.	Does the patient have a history of hematologic abnormalities?						
	If yes, please provide date(s):						
6.	· · · · · · · · · · · · · · · · · · ·						
_	180 days?	<del></del>					
7.							
	If no, does the patient have a contraindication to or is non-responsive to DMARD therapy? Yes □ N						
	Please list all reasons for selecting the requested medication, strength,						
allergies, or history of adverse drug reactions to alternatives, lower dose has been tried).							
9.	Please list all other medications the patient is currently taking for treatment	ent of this diagnosis.					
	10. Please list the medications the patient has <b>previously tried and failed</b> for treatment of this diagnosis (Please specify if brand name, generic, extended-release products, or OTC products):						
	Date(s):	Date(s):					
	Date(s):	Date(s):					
	Date(s):	Date(s):					
Plea	se continue on page 2.						

Patient Name (First):	Last:		M:	DOB (mm/dd/yyyy):				
For Humira Requests:								
11. Has the patient had a 30-day trial with conventional therapy in the last 90 days?								
If yes, please document agent tried:								
For Kevzara Requests:								
12. Does the patient have a diagnosis of active hepatic disease or hepatic impairment in the last 365 days?								
For Olumiant Requests:								
13. Does the patient have a diagnosis that indicates increased risk of GI perforation, thrombosis, or malignancy in								
the last 180 days? Yes No								
14. Does the patient have a diagnosis of seve	Does the patient have a diagnosis of severe renal (eGFR <60 mL/min/1.73m²) or severe hepatic impairment in the last 365 days?							
in the last 365 days?								
For Otezla Requests:								
15. Does the patient have a diagnosis of chronic kidney disease (stage 4 or 5) in the last 365 days? Yes □ No								
For Rinvoq Requests:								
16. Has the patient tried methotrexate?	6. Has the patient tried methotrexate? Yes ☐ No							
If no, does the patient have an inade	If no, does the patient have an inadequate response or intolerance to methotrexate? ☐ Yes ☐ No							
17. Does the patient have a diagnosis of severe hepatic impairment in the last 365 days?								
For Siliq Requests:								
18. Has the patient had a 30-day trial with conventional therapy for plaque psoriasis in the last 90 days? ☐ Yes ☐ No								
If yes, please document agent tried:								
19. Does the patient have a diagnosis of Crohn's disease in the last 365 days? Yes □ No								
For Stelara Requests:								
20. Has the patient had a 30-day trial for an immunomodulator, corticosteroid, or TNF blocker in the last 180 days? . Tes No								
For Taltz Requests:								
21. Does the patient have a diagnosis of Crohn's disease or ulcerative colitis in the last 365 days?								
Prescriber or Authorized Signature:		Date: _						
Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for a patient. Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations, and exclusions. The submitting provider certifies that the information provided is true, accurate, and complete and the requested services are medically indicated and necessary to the health of the patient.  Note: Payment is subject to member eligibility Authorization does not guarantee payment.								
Please fax or mail this form to:  Prime Therapeutics LLC, Clinical Review Department  CONFIDENTIALITY NOTICE: This communication is intended only for the use of the individual entity to which it is addressed and may contain								
Prime Therapeutics LLC, Clinical Review Departr 2900 Ames Crossing Road	information that is privileged or confi	dential. I	If the reader of this					
Eagan, Minnesota 55121	message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly							
TOLL FREE prohibited. If you have received this communication in error				nication in error, please				
Fax: 877.243.6930 Phone: 855.457.0407 notify the sender immediately by telephone at 866.202.3474 the original message to Prime Therapeutics via U.S. Mail. The for your cooperation.								